These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 21898393)
21. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Hallez S; Simon P; Maudoux F; Doyen J; Noël JC; Beliard A; Capelle X; Buxant F; Fayt I; Lagrost AC; Hubert P; Gerday C; Burny A; Boniver J; Foidart JM; Delvenne P; Jacobs N Cancer Immunol Immunother; 2004 Jul; 53(7):642-50. PubMed ID: 14985860 [TBL] [Abstract][Full Text] [Related]
22. Induction of human papillomavirus oncogene-specific CD8 T-cell effector responses in the genital mucosa of vaccinated mice. Decrausaz L; Revaz V; Bobst M; Corthésy B; Romero P; Nardelli-Haefliger D Int J Cancer; 2010 May; 126(10):2469-78. PubMed ID: 19816937 [TBL] [Abstract][Full Text] [Related]
23. A novel recombinant protein vaccine containing the different E7 proteins of the HPV16, 18, 6, 11 E7 linked to the HIV-1 Tat (47-57) improve cytotoxic immune responses. Mousavi T; Valadan R; Rafiei A; Abbasi A; Haghshenas MR Biotechnol Lett; 2021 Sep; 43(9):1933-1944. PubMed ID: 34313864 [TBL] [Abstract][Full Text] [Related]
24. Herpes Simplex Virus Glycoprotein D Targets a Specific Dendritic Cell Subset and Improves the Performance of Vaccines to Human Papillomavirus-Associated Tumors. Porchia BFMM; Moreno ACR; Ramos RN; Diniz MO; de Andrade LHTM; Rosa DS; Barbuto JAM; Boscardin SB; Ferreira LCS Mol Cancer Ther; 2017 Sep; 16(9):1922-1933. PubMed ID: 28522585 [TBL] [Abstract][Full Text] [Related]
25. Enhanced anti-tumor effects of HPV16E7(49-57)-based vaccine by combined immunization with poly(I:C) and oxygen-regulated protein 150. Chen S; Ou R; Tang J; Deng X; Wu Y; van Velkinburgh JC; Ni B; Xu Y Cancer Epidemiol; 2013 Apr; 37(2):172-8. PubMed ID: 23127963 [TBL] [Abstract][Full Text] [Related]
26. Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model. Jia Y; Yin Y; Duan F; Fu H; Hu M; Gao Y; Pan Z; Jiao X Int J Mol Med; 2012 Dec; 30(6):1335-42. PubMed ID: 23027427 [TBL] [Abstract][Full Text] [Related]
27. Therapeutic dendritic cell vaccination with Ag coupled to cholera toxin in combination with intratumoural CpG injection leads to complete tumour eradication in mice bearing HPV 16 expressing tumours. Chandy AG; Nurkkala M; Josefsson A; Eriksson K Vaccine; 2007 Aug; 25(32):6037-46. PubMed ID: 17629599 [TBL] [Abstract][Full Text] [Related]
29. CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour model. Kim TG; Kim CH; Won EH; Bae SM; Ahn WS; Park JB; Sin JI Immunology; 2004 May; 112(1):117-25. PubMed ID: 15096191 [TBL] [Abstract][Full Text] [Related]
30. A novel "priming-boosting" strategy for immune interventions in cervical cancer. Liao S; Zhang W; Hu X; Wang W; Deng D; Wang H; Wang C; Zhou J; Wang S; Zhang H; Ma D Mol Immunol; 2015 Apr; 64(2):295-305. PubMed ID: 25575128 [TBL] [Abstract][Full Text] [Related]
31. Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation. Wu CY; Monie A; Pang X; Hung CF; Wu TC J Biomed Sci; 2010 Nov; 17(1):88. PubMed ID: 21092195 [TBL] [Abstract][Full Text] [Related]
32. Fungal mannosylation enhances human papillomavirus 16 E7 therapeutic immunity against TC-1 tumors. Wang Z; Wei C; Zhang Y; Wang W; Zhou Z; Xiao G Oncol Rep; 2018 Jan; 39(1):425-432. PubMed ID: 29115562 [TBL] [Abstract][Full Text] [Related]
33. Synergy effects of Polyinosinic-polycytidylic acid, CpG oligodeoxynucleotide, and cationic peptides to adjuvant HPV E7 epitope vaccine through preventive and therapeutic immunization in a TC-1 grafted mouse model. Liu C; Chu X; Sun P; Feng X; Huang W; Liu H; Ma Y Hum Vaccin Immunother; 2018 Apr; 14(4):931-940. PubMed ID: 29271696 [TBL] [Abstract][Full Text] [Related]
34. Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice. Domingos-Pereira S; Decrausaz L; Derré L; Bobst M; Romero P; Schiller JT; Jichlinski P; Nardelli-Haefliger D Mucosal Immunol; 2013 Mar; 6(2):393-404. PubMed ID: 22968420 [TBL] [Abstract][Full Text] [Related]
35. Intravaginal Administration of Fc-Fused IL7 Suppresses the Cervicovaginal Tumor by Recruiting HPV DNA Vaccine-Induced CD8 T Cells. Choi YW; Kang MC; Seo YB; Namkoong H; Park Y; Choi DH; Suh YS; Lee SW; Sung YC; Jin HT Clin Cancer Res; 2016 Dec; 22(23):5898-5908. PubMed ID: 27407095 [TBL] [Abstract][Full Text] [Related]
36. Enhanced therapeutic effects conferred by an experimental DNA vaccine targeting human papillomavirus-induced tumors. Diniz MO; Cariri FA; Aps LR; Ferreira LC Hum Gene Ther; 2013 Oct; 24(10):861-70. PubMed ID: 24007495 [TBL] [Abstract][Full Text] [Related]
38. Human papillomavirus (HPV) type 16 E7 protein bodies cause tumour regression in mice. Whitehead M; Ohlschläger P; Almajhdi FN; Alloza L; Marzábal P; Meyers AE; Hitzeroth II; Rybicki EP BMC Cancer; 2014 May; 14():367. PubMed ID: 24885328 [TBL] [Abstract][Full Text] [Related]
39. A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice. Granadillo M; Vallespi MG; Batte A; Mendoza O; Soria Y; Lugo VM; Torrens I Vaccine; 2011 Jan; 29(5):920-30. PubMed ID: 21145912 [TBL] [Abstract][Full Text] [Related]
40. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication. Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]